Sale of two Novartis sites to Siegfried Holding AG

Healthcare / Industrials
Deal type
Sell your business / Carve out
December 2020
Countries involved
Switzerland / Spain


Novartis AG researches, develops, manufactures and markets healthcare products worldwide. It is a multi-national pharmaceuticals producer with core competencies in cardio-metabolic, immunology & neuroscience medicine, producing both branded and private label pharmaceuticals


Capitalmind has advised Novartis on the sale of two manufacturing sites in Spain to Siegfried Holding AG


Lead team

  • Arne Laarveld

    Arne Laarveld

    Partner Germany
  • Ervin Schellenberg

    Ervin Schellenberg

    Managing Partner Germany

About the Deal

Novartis has entered into an agreement with Siegfried Holding AG, a leading Contract Development & Manufacturing Organization. Siegfried will acquire the Novartis manufacturing sites at Barberà del Vallès and El Masnou (Spain) and will become a key supplier to Novartis.

The Novartis portfolio is changing. As biomedical research advances and breakthrough therapies become available, Novartis is adjusting its capacity and capabilities to a new set of requirements.

Switzerland-based Siegfried will take over responsibility for all manufacturing activities at Barberà del Vallès and El Masnou production centers and both sites remain important supply points for Novartis.

What we did

Advising and supporting the lead project managers on:

  • Project management tasks
  • Project governance
  • Due diligence coordination/support
  • Operational Carve out issues
  • Support of documentation (contract annexes and schedules)
  • Project management and team support

Yulia Pogodina, Global Project Lead Novartis: “The Capitalmind team delivered a highly reliable support on project management level and has integrated perfectly into the global and local parts of the project teams. Having been involved in project management as well as operational tasks, Capitalmind provided valuable input and support to the project lead.”